AbCellera Announces Changes to Its Board of Directors
07 Dicembre 2021 - 3:00PM
Business Wire
AbCellera (Nasdaq: ABCL), a technology company with a
centralized operating system for next-generation antibody
discovery, today announced changes to its Board of Directors with
the appointment of Andrew W. Lo, Ph.D., as an independent director
and the resignation of John Hamer, Ph.D. Changes are effective
immediately.
Dr. Lo has developed new financial engineering tools and
business models for drug and device development and healthcare
delivery, statistical methods for incorporating patient preferences
into the drug approval process, and machine-learning for predicting
clinical trial outcomes. He will serve on the Audit and
Compensation Committees of the Board of Directors.
“Andrew is a distinguished economist, professor, author, and
strategist whose work in connecting financial structures, business
models, and biomedical innovation has resulted in exciting new
approaches that help bring treatments to patients faster,” said
Carl Hansen, Ph.D., CEO, President, and Chairperson of AbCellera.
“We welcome him to our board and look forward to working with him
as we continue to build a large and diversified portfolio of
positions in the next generation of antibody therapies, driving
long-term value for patients, partners, and our shareholders.”
“I'm delighted and honored to be joining AbCellera's board.
Their unique partnership-based business model draws on key
financial insights to build value,” said Dr. Lo. “I look forward to
working with them to help them realize the enormous impact their
approach can have on the industry and, ultimately, on patients
around the world."
Dr. Lo is a cofounder and director of BridgeBio Pharma, a
director of Atomwise and Roivant Sciences, a cofounder and chairman
of QLS Advisors, and a member of the advisory boards of NCATS and
the American Cancer Society’s BrightEdge Impact Fund. He is
currently the Charles E. and Susan T. Harris Professor at the MIT
Sloan School of Management, director of MIT’s Laboratory for
Financial Engineering, and principal investigator at MIT's Computer
Science and Artificial Intelligence Laboratory. Dr. Lo was named
one of TIME’s “100 most influential people in the world.”
Dr. Hamer, Managing Partner at DCVC Bio, joined AbCellera’s
Board in 2018 and has served on the Audit and Compensation
Committees.
“John has been a valued investor and director for AbCellera. He
recognized the company’s potential early and brought a unique
combination of scientific, operational, and financial expertise
that was instrumental in getting us to where we are today,” said
Dr. Hansen. “It has been a distinct pleasure working with him over
the last three years. We thank him for his guidance and wish him
the best as he continues to find and build new companies at the
interface of computation and biotechnology.”
About AbCellera Biologics Inc. AbCellera is a technology
company that searches, decodes, and analyzes natural immune systems
to find antibodies that its partners can develop into drugs to
prevent and treat disease. AbCellera partners with drug developers
of all sizes, from large pharmaceutical to small biotechnology
companies, empowering them to move quickly, reduce cost, and tackle
the toughest problems in drug development. For more information,
please visit www.abcellera.com.
AbCellera Forward-looking Statements This press release
contains forward-looking statements, including statements made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The forward-looking statements are
based on management’s beliefs and assumptions and on information
currently available to management. All statements contained in this
release other than statements of historical fact are
forward-looking statements, including statements regarding our
ability to develop, commercialize and achieve market acceptance of
our current and planned products and services, our research and
development efforts, and other matters regarding our business
strategies, use of capital, results of operations and financial
position, and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by
the words “may,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “ongoing” or the negative of
these terms or other comparable terminology, although not all
forward-looking statements contain these words. These statements
involve risks, uncertainties and other factors that may cause
actual results, levels of activity, performance, or achievements to
be materially different from the information expressed or implied
by these forward-looking statements. These risks, uncertainties and
other factors are described under "Risk Factors," "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" and elsewhere in the documents we file with the
Securities and Exchange Commission from time to time. We caution
you that forward-looking statements are based on a combination of
facts and factors currently known by us and our projections of the
future, about which we cannot be certain. As a result, the
forward-looking statements may not prove to be accurate. The
forward-looking statements in this press release represent our
views as of the date hereof. We undertake no obligation to update
any forward-looking statements for any reason, except as required
by law.
Source: AbCellera Biologics Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211207005444/en/
Inquiries Media: Jessica Yingling, Ph.D.;
media@abcellera.com, +1(236) 521-6774 Business Development: Neil
Berkley; bd@abcellera.com, +1(604) 559-9005 Investor Relations:
Melanie Solomon; ir@abcellera.com, +1(778) 729-9116
Grafico Azioni AbCellera Biologics (NASDAQ:ABCL)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni AbCellera Biologics (NASDAQ:ABCL)
Storico
Da Lug 2023 a Lug 2024